MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

British Journal of Haematology

Volumn 99, Issue 1, 1997, Pages 76-83

  Van Den Heuvel Eibrink, Marry M ^a,b   Van Der Holt, Bronno ^a   Te Boekhorst, Peter A W ^a   Pieters, Rob ^c   Schoester, Martijn ^a   Löwenberg, Bob ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Multidrug resistance; Prognostic factors

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; HUMAN; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030729284     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3343148.x     Document Type: Article

References (40)

1. Arceci, R.J. (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81, 2215-2222.
2. Arthur, D., Berger, R., Colomb, H., Swansbury, G., Reeves, B.G.A., Berghe, H. v.d., Boomfield, C., Capelle, A., Dewald, G., Garson, O., Hagemeijer, A., Kaneko, Y., Mitelman, F., Pierre, R., Ruutu, T., Sakurai, M., Lawler, S. & Rowley, J. (1989) The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genetics and Cytogenetics, 40, 203-216.
3. Beck, W.T., Grogan, T.M., Willman, C.L., Cordon-Cardo, C., Parham, D.M., Kuttesch, J.F., Andreeff, M., Bates, S.E., Berard, C.W., Boyett, J.M., Brophy, N.A., Broxterman, H.J., Chan, H.S.L., Dalton, W.S., Dietel, M., Fojo, A.T., Gascoyne, R.D., Head, P., Houghton, P.J., Srivastava, D.K., Lehnert, M., Leith, C.P., Paietta, E., Pavelic, Z.P., Rimsza, L., Roninson, I.B., Sikic, B.I., Twentyman, P.R., Warnke, R. & Weinstein, R. (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Research, 56, 3010-3020.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Grainick, H.R. & Sultan, C. (1985) Proposed revised criteria for classification of myeloid leukemia: a report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620-625.
5. Bishop, J.F., Mattews, J.P. & Young, G.A. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710-1717.
6. Bradley, G., Jurunka, P.F. & Ling, V. (1988) Mechanisms of multidrug resistance. Biochimica et Biophysica Acta, 948, 87-128.
7. Broxtermann, H.J., Sonneveld, P., Feller, N., Ossenkoppele, G.J., Währer, D.C.R., Eekman, C.A., Schoester, M., Lankelma, J., Pinedo, H.M., Löwenberg, B. & Schuurhuis, G.J. (1996) Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood, 87, 4809-4816.
8. Buchner, T., Urbanitz, D., Hiddemann, W., Ruhl, H., Ludwitg, W.D., Fischer, J., Aul, H.C., Vaupel, H.A., Kuse, R. & Zeile, G. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. Journal of Clinical Oncology, 3, 1583-1589.
9. Campos, L., Guyot, D. & Archimbaud, E. (1989) Surface marker expression in adult myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. British Journal of Haematology, 72, 161-166.
10. Campos, L., Guyotat, D., Archimabud, E., Calmard-Oriol, P., Tsuruo, T., Trancy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia at diagnosis. Blood, 73, 473-476.
11. Cassileth, P.A., Lynch, E., Hines, J.D., Oken, M.M., Mazza, J.J., Bennett, J.M., McGlare, P.B., Edelstein, M., Harrington, D.P. & O'Connell, M.J. (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79, 1924-1930.
12. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society, B34, 187-220.
13. Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M.C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. & Papa, G. (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 87, 1007-2004.
14. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzannaeu, G. & Tilly, H. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine, 332, 1678-1683.
15. Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C. & Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flowcytometry. Blood, 85, 2147-2153.
16. Hagemeijer, A., Smit, A.M.E. & Bootsma, D. (1979) Improved identification of leukemic cells in methotrexate treated cultures. Cytogenetics and Cell Genetics, 23, 208-210.
17. Hamblin, T.J. (1995) Disappointments in treating acute leukemia in the elderly. New England Journal of Medicine, 332, 1712-1713.
18. Holmes, J.A. & West, R.R. (1994) The effect of MDR 1 gene expression on outcome in acute myeloblastic leukaemia. British Journal of Cancer, 69, 382-384.
19. Hosmer, D.W., Jr & Lemshow, S. (1989) Applied Logistic Regression John Wiley & Sons, New York.
20. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
21. - cases. Blood, 86, 2329-2336.
22. List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. & Dalton, W. (1994) Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. Journal of Clinical Oncology, 11, 1652-1660.
23. Löwenberg, B., Van Putten, W.L.J., Touw, I.P., Delwel, R. & Santini, V. (1993) Autonomous growth determines prognosis in acute myeloid leukemia. New England Journal of Medicine, 328, 614-619.
24. Löwenberg, B., Van Putten, W.L.J., Verdonck, L.F., Dekker, A.W., De Gast, C.G., Willemze, R., Zwaan, F.E., De Planque, H., Abels, J., Sonneveld, P., Van der Lelie, J., Goudsmit, R., Sizoo, W. & Hagenbeek, A. (1990) Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. Journal of Clinical Oncology, 8, 287-294.
25. Machnicki, J.L. & Bloomfield, C.D. (1990) Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia. Clinics in Laboratory Medicine, 10, 755-767.
26. Mantel, N. (1966) Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
27. Marie, J.P., Zittoun, R. & Sikic, B.I. (1991) Multidrug resistance (MDR 1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592.
28. Mayer, J.R., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E. (1994) Third intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903.
29. Mitelman, F. (1991) ISCN Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature, Karger, Basel.
30. Rees, J.K.H., Gray, R.G., Swirsky, D. & Hayhoe, F.G.J. (1986) Principal results of the Medical Reseach Council's 8th Acute Myeloid Leukaemia Trial. Lancet, ii, 1236-1241.
31. Salmon, S.E., Dalton, W.S., Grogan, T.M., Plezia, P., Lehnert, M., Roe, D.J. & Miller, T.P. (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78, 44-50.
32. Samdani, A., Vijapurkar, U., Grimm, M.A., Spier, C.S., Grogan, T.M., Glinsmann-Gibson, B.J. & List, A.F. (1996) Cytogenetics and P-glycoprotein (P-gp) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leukemia Research, 20, 175-180.
33. Sonneveld, P., Durie, B.G.M., Lokhorst, H.M., Marie, J.P. de, Solbu, G., Suciu, S., Zittoun, R. & Löwenberg, B. (1992) Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet, 340, 255-259.
34. te Boekhorst, P.A.W., Löwenberg, B., Van Kapel, J. & Sonneveld, P., (1995) Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia, 9, 1025-1031.
35. te Boekhorst, P.A.W., Wittebol, S., Hagemeijer, A., Löwenberg, B. & Sonneveld, P. (1993) Predominance of the multidrug resistance (MDR 1) phenotype in acute myeloid leukemia cells is associated with an immature (CD34) phenotype. Blood, 10, 3157-3162.
36. Van Dongen, J.J.M., Adriaansen, H.J. & Hooijkaas, H. (1989) Immunological marker analysis of cells in the various hematopoietic differentiation stages and their malignant counterparts. Application of Monoclonal Antibodies in Tumour Pathology (ed. by D. J. Ruiter, G. J. Fleuren and S. O. Warnaar), pp. 87-116. Martinus Nijhoff, Dordrecht.
37. Vogler, W.R., Winton, E.F., Gordon, D.S., Raney, M.R., Go, B. & Meyer, L. (1984) A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood, 63, 1039-1045.
38. Wood, P., Burgess, R., MacGregor, A. & Liu Yin, J.A. (1994) P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. British Journal of Haematology, 87, 509-514.
39. Yates, J.W., Glidewell, O., Wiernik, P.H., Cooper, M.R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchinson, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood, 60, 454-462.
40. Zittoun, R.A., Mandelli, F., Willemze, R., Witte, T.D., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Strickmans, P., Rotoli, B., Leoni, P., Peetermans, M., Dardenne, M., Vegna, M., Petti, M., Solbu, G. & Suciu, S. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine, 332, 217-223.